Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nektar

Essential new MIDI controllers for 2023

GEAR EXPO 2023: The best devices coming out this year to take back control of your hardware and software

NAMM 2023: The best new music tech gear of the show

NAMM 2023: The best new music tech gear of the show

Our top synth, monitor, controller, interface, groovebox and plugin picks

NAMM 2023: With the Panorama CST MIDI controller, Nektar hopes to make music production a lot less about staring at a computer screen

NAMM 2023: With the Panorama CST MIDI controller, Nektar hopes to make music production a lot less about staring at a computer screen

Channel strip controller uses colour coding and easy mapping to make mixing more accessible and creative

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Healthcare companies PureTech and Nektar scrap merger plans

News of a potential merger had only come to light last Friday

Evening Standard

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

Here's a roundup of top developments in the biotech space over the last 24 hours:

After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring

Nektar Therapeutics (NASDAQ:NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team. Dimitry Nuyten, Nektar's Chief Medical Officer, will step down from his position following June 2022. He will be succeeded by Brian Kotzin, Nektar's Head of…

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Nektar Shares Are Down Almost 35%

Why Nektar Shares Are Down Almost 35%

Shares of Nektar Therapeutics (NASDAQ: NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in collaboration with Bristo,” according to BofA Securities.

Why Nektar Therapeutics Shares Are Falling Today

Why Nektar Therapeutics Shares Are Falling Today

Nektar Therapeutics (NASDAQ: NKTR) is trading significantly lower Monday morning after the company's Phase 3 PIVOT trial, in combination with Bristol-Myers Squibb Co (NYSE: BMY), did not meet its primary endp

1 2

Organisations

BofA Securities

Nektar rapeutics

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Ulcerative Colitis

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play